KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Common Equity (2016 - 2025)

Biogen (BIIB) has 17 years of Common Equity data on record, last reported at $18.3 billion in Q4 2025.

  • For Q4 2025, Common Equity rose 9.22% year-over-year to $18.3 billion; the TTM value through Dec 2025 reached $18.3 billion, up 9.22%, while the annual FY2025 figure was $18.3 billion, 9.22% up from the prior year.
  • Common Equity reached $18.3 billion in Q4 2025 per BIIB's latest filing, up from $51.6 million in the prior quarter.
  • Across five years, Common Equity topped out at $18.3 billion in Q4 2025 and bottomed at -$2.6 million in Q4 2023.
  • Average Common Equity over 5 years is $12.6 billion, with a median of $13.6 billion recorded in 2022.
  • Peak YoY movement for Common Equity: crashed 100.02% in 2023, then skyrocketed 643023.08% in 2024.
  • A 5-year view of Common Equity shows it stood at $11.0 billion in 2021, then increased by 22.16% to $13.4 billion in 2022, then crashed by 100.02% to -$2.6 million in 2023, then surged by 643023.08% to $16.7 billion in 2024, then rose by 9.22% to $18.3 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $18.3 billion in Q4 2025, $51.6 million in Q3 2025, and $17.6 billion in Q2 2025.